Vrije Universiteit Brussel

Faculté Universitaire Des Sciences Agronomiques De Gembloux

Université Libre De Bruxelles

Universitéde Liége

N.v. Innogenetics S.a.

Aventis Pasteur S.a.

Robert Brasseur

Laurence Lins

Frederic Camu

Franz Legros

Michel Chevalier

Christine Labeur

Edmond Godfroid

Robert J Deleys

Luc Vanhamme

Tino Krell

Regis Sodoyer

Benoit Charloteaux

Maryvonne Rosseneu

Oliver Bouffioux

Mokarram Alafandy

Sandra Carlino

Raphaelle El Habib

Ngoc-Quynh-Nhu Nguyen

Ingrid Struman

Joseph Martial

Sébastien Santini

Benoît Adam

Jérôme Beaufays

Marc Decaffmeyer

Ernst Heinen

Leukotriene B4 binding polypeptide is obtained from Ixodes ricinus. Leukotriene B4 polypeptide, the polynucleotide encoding Leukotriene B4 polypeptide, and Leukotriene B4 polypeptide related polypeptides may be used as research reagents and for treatments and diagnostics specific to animal and human diseases.

Leukotriene B4 binding soluble lipocalin receptor from ixodes ricinus

The present invention refers to a pharmaceutical composition comprising an isolated antiangiogenic peptide or a recombinant protein comprising the antiangiogenic peptide, wherein the peptide is between 11 and 40 amino acids in length and having antiangiogenic activity, the peptide comprising the amino acid sequence: X1-X2-X3-X4-X5-X6-X7-X8-X9-X10-X11-X12-X13-X14, wherein X1 is any amino acid residue compatible with forming a helix; X2 is an amino acid residue of: Leu, Ile, Val; X3 is an amino acid residue of: Arg, Lys, His, Ser, Thr; X4 is an amino acid residue of: Ile, Leu, Val; X5 is any amino acid residue compatible with forming a helix; X6 is an amino acid residue of: Leu, Ile, Val; X7 is an amino acid residue of: Leu, Ile, Val, Ser, Thr; X8 is any amino acid residue compatible with forming a helix; X9 is any amino acid residue compatible with forming a helix; X10 is an amino acid residue of: Gln, Glu, Asp, Arg, His, Lys, Asn; X11 is an amino acid residue of: Ser, Thr; X12 is an amino acid residue of: Trp, Tyr, Phe; X13 is an amino acid residue of: Leu, Ile, Val, Asn, Gln; X14 is an amino acid residue of: Glu, Gln, Asp, Asn.

Antiangiogenic peptides

The present invention thus provides a polypeptide capable of forming a structure corresponding to or mimicking the intermediate of gp41 as well as its use in a vaccine for treating or preventing HIV infections.

Polypeptide inducing antibodies neutralizing HIV

A process for the preparation of freeze dried liposome encapsulated amphiphilic drug compositions, which process comprises preparing a liposomal suspension of multilamellar vesicles (MLVs) which encapsulate an amphiphilic drug compsition, adding sorbitol to the liposomal suspension and lyophilisation of the suspension.

Freeze dried liposome encapsulated amphiphilic drug compositions and a process for the preparation thereof

Liposome encapsulated amphiphilic drug compositions

Peptides and proteins, process for their preparation and their use as

Growing community of inventors

Haillot, Belgium

Robert Brasseur